The writer of this paper sets out the argument that the pharma industry is waking up to two new disruptive trends which affect the pricing of drugs, namely paying for value and outcomes and new patient information technologies (PI). This is propelling the industry towards a new business model of greater payer engagement and outcome. Read more here. (Source: thepharmaletter, 11/11/14).
You are here: / / Outcome-Based Data And Value Are Vital For Payers And HTAs